A Phase 1 interventional study of RTx-015 in retinitis pigmentosa

Active, Not Recruiting Phase 1 NCT06460844

Study Description

A study to evaluate the safety of a gene therapy treatment (RTx-015) for retinitis pigmentosa

Study Details

Registry ID:: NCT06460844
Conditions:: Retinitis Pigmentosa, Choroideremia
Phase:: Phase 1
Target Enrollment:: 10 participants
Start Date:: August 27, 2024
Age Range:: 18–999 years
Healthy Volunteers:: No

Study Locations (4 sites)

UPMC Vision Institute
Pittsburgh, PennsylvaniaUnited States, United States
Retina Consultants of Texas Research Centers
Bellaire, TexasUnited States, United States
UCI Alpha Clinic
Orange, CaliforniaUnited States, United States
Retina Vitreous Associates Medical Group
Beverly Hills, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →